Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...

Descrición completa

Detalles Bibliográficos
Main Authors: Peng-Fei Zhang, Dan Xie, Qiu Li
Formato: Artigo
Idioma:English
Publicado: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Public Health
Subjects:
prostate cancer
enzalutamide
cost-effectiveness
androgen deprivation therapy
first-line
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full

Títulos similares

Títulos similares